30 October 2019
Celldex stops Phase Ib/II trial in melanoma due to GI toxicities after enrolling three patients
The study had enrolled three out of its 10-patient target when it was stopped, a source said.
Trending menu:
Comment
-
-
25 October 2019
Amgen’s AMG510 combo exploration in colorectal cancer tumours poised for late 2019, early 2020
The theory behind combining AMG510 with a MEK inhibitor in CRC is that together they would target upstream and downstream KRAS events.
-
24 October 2019
UCB to conduct bridging study of UCB0107 in progressive supranuclear palsy this year
The bridging study will be necessary to provide the safety and pharmacokinetic data needed to advance the anti-tau drug into a Phase III trial planned for 2020.
-
23 October 2019
Lay of the land for lupus in the last decade
Systemic lupus erythematous, commonly known as Lupus (Latin for wolf), is a systemic autoimmune disease that predominately affects women of childbearing age.
-
23 October 2019
Pfizer unveils top-line Phase III results for abrocitinib study
Atopic dermatitis is a chronic skin disease characterised by inflammation and skin barrier defects that affects up to 10% of adults and up to 20% of children worldwide.
-
21 October 2019
Karuna’s Phase II schizophrenia trial prompts expert caution
Eli Lilly’s xanomeline had previously been researched in Alzheimer’s disease and schizophrenia by independent researchers and was found to significantly improve behavioural symptoms.
-
21 October 2019
Theravance to recruit 120 trial sites for Phase III trial in neurogenic orthostatic hypotension
neurogenic orthostatic hypotension is a rare subtype of orthostatic hypotension caused by underlying neurologic disorders that affect a specific part of the autonomic nervous system.
-
21 October 2019
KalVista’s hereditary angioedema treatment draws uncertainty
HAE is characterised by recurrent episodes of severe swelling (angioedema). The most frequent areas of the body to develop swelling are the limbs, face, intestinal tract and the airway.
-
14 October 2019
Taltz knocks down Tremfya in head-to-head trial in psoriasis patients
Patients treated with Taltz demonstrated statistically significantly higher improvements than those treated with Tremfya as measured by PASI 100 at Week 12.
-
10 October 2019
ESMO 2019: Delegates told refractory metastatic renal cell carcinoma is an unmet need with great growth potential
According to expert opinion, 20─30% of patients with stage I–III localised tumours will relapse after nephrectomy and progress to stage IV metastatic RCC, which requires systemic drug therapy.